Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03163667 · ClinicalTrials.gov registry record · Phase 2
CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)
A Phase 2 study of Clear Cell Renal Cell Carcinoma, sponsored by Calithera Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
- 20
- Study locations
NCT03163667 is a Phase 2 study of Clear Cell Renal Cell Carcinoma that has completed, run by Calithera Biosciences. The registered enrollment target is 69 participants, below the 202-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (66% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT03163667, a Phase 2 study of Clear Cell Renal Cell Carcinoma, has completed, sponsored by Calithera Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to compare the progression-free survival (PFS) of participants treated with telaglenastat and everolimus versus placebo and everolimus for advanced or metastatic clear cell renal cell carcinoma (ccRCC) previously treated with the following: * At least 2 lines of therapy, including at least 1 vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) * Radiographic progression of metastatic RCC must have occurred (per investigator assessment) on or after the most recent systemic therapy and within 6 months prior to cycle 1 day 1
Conditions Studied
Interventions
- DRUG Placebo
- DRUG everolimus
- DRUG CB-839
Study Locations (20)
California
- Los Angeles Hematology Oncology Medical Group - Los Angeles
- UCLA Department of Medicine - Hematology/Oncology - Los Angeles
- Stanford Cancer Center - Stanford
Florida
- Florida Cancer Specialists- South - Fort Myers
- Florida Cancer Specialists- North - St. Petersburg
Georgia
- University Cancer & Blood Center, LLC - Athens
- Northwest Georgia Oncology Centers, P.C. - Marietta
Maryland
- Anne Arundel Medical Center Oncology and Hematology - Annapolis
- University of Maryland, Greenebaum Comprehensive Cancer Center - Baltimore
Missouri
- Mercy Clinic Oncology & Hematology - Joplin
- SCRI HCA Midwest - Kansas City
Arizona
- The University of Arizona Cancer Center - Tucson
Arkansas
- Highlands Oncology Group - Rogers
Idaho
- St. Luke's Mountain States Tumor Institute - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2017-09-06 |
| Est. Completion | 2020-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03163667
The ClinicalTrials.gov registry entry for NCT03163667 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 202-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (66% lower). The listed sponsor is Calithera Biosciences, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03163667 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT03163667 about?
NCT03163667 is a clinical study titled "CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)". The primary objective of this study is to compare the progression-free survival (PFS) of participants treated with telaglenastat and everolimus versus placebo and everolimus for advanced or metastatic clear cell renal cell carcinoma (ccRCC) previously treated with the following: * At least 2 lines ...
What is the current status of trial NCT03163667?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2017-09-06. Estimated completion is 2020-06-01.
What conditions does trial NCT03163667 study?
This clinical trial studies the following conditions: Clear Cell Renal Cell Carcinoma.
What interventions are being tested in trial NCT03163667?
The interventions under investigation include: Placebo (DRUG), everolimus (DRUG), CB-839 (DRUG).
Who is sponsoring clinical trial NCT03163667?
This trial is sponsored by Calithera Biosciences, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03163667 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clear Cell Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
RECRUITING · Phase 2
-
An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
RECRUITING · Phase 2
-
Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
-
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
RECRUITING · Phase 2
-
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.